纳米颗粒的封装HBV-CPG诱导治疗对乙肝病毒感染的免疫力

StephenW

Hepatology. 2013 Aug 1. doi: 10.1002/hep.26654. [Epub ahead of print]
Nanoparticles encapsulating HBV-CpG induce therapeutic immunity against hepatitis B virus infection.
Lv S, Wang J, Dou S, Yang X, Ni X, Sun R, Tian Z, Wei H.
Source

Institute of Immunology, Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, China; Department of Microbiology, Anhui Medical University, Hefei, China.
Abstract

Infection with hepatitis B virus (HBV) is the most common cause of liver disease worldwide. However, because the current interferon (IFN)-based treatments have toxic side effects and marginal efficacy, improved antivirals are essential. Here, we report that unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODNs) from the HBV genome (HBV-CpG) induced robust expression of IFN-α by plasmacytoid dendritic cells (pDCs) in a TLR9-dependent manner. We also identified inhibitory guanosine-rich ODNs in the HBV genome (HBV-ODN) that are capable of inhibiting HBV-CpG-induced IFN-α production. Furthermore, nanoparticles containing HBV-CpG, termed NP(HBV-CpG), reversed the HBV-ODN-mediated suppression of IFN-α production and also exerted a strong immunostimulatory effect on lymphocytes. Our results suggest that NP(HBV-CpG) can enhance the immune response to HBsAg and skew this response toward the Th1 pathway in mice immunized with rHBsAg and NP(HBV-CpG). Moreover, NP(HBV-CpG)-based therapy led to the efficient clearance of HBV and induced an anti-HBsAg response in HBV carrier mice. Conclusion: We propose that endogenous HBV-CpG ODNs from the HBV genome induce IFN-α production and that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection. (Hepatology 2013;).

StephenW

纳米颗粒的封装HBV-CPG诱导治疗对乙肝病毒感染的免疫力。
吕S，王J，窦●后，杨新，以Ni x，孙睿，田铮，魏H.
源

免疫学研究所，合肥微尺度物质科学国家实验室和学校生命科学学院，科技大学和中国科技，合肥，中国微生物学系，安徽医科大学，合肥，中国。

摘要
与B型肝炎病毒（HBV）感染是世界范围内的肝脏疾病的最常见原因。然而，因为目前的干扰素（IFN）为基础的治疗具有毒性的副作用和疗效边缘，改进的抗病毒药物是必不可少的。在这里，我们报告说，非甲基化胞嘧啶 - 磷酸鸟苷的寡核苷酸（CpG寡核苷酸的）HBV基因组（HBV-CPG）在TLR9依赖性浆细胞树突状细胞（pDCs细胞）的IFN-α诱导表达的强劲。我们还确定了在HBV基因组（HBV-ODN），能抑制HBV的CpG诱导的IFN-α生成的抑制富含鸟苷的反义寡核苷酸。此外，纳米粒子含有HBV-CPG，称为NP（HBV-CPG），扭转了HBV反义寡核苷酸介导的抑制α-干扰素生产也产生了强烈的对淋巴细胞的免疫效果。我们的研究结果表明，NP（HBV-CPG）可以增强rHBsAg和NP（HBV-CPG）免疫小鼠Th1细胞通路的这种反应向HBsAg和歪斜的免疫反应。此外，NP（HBV-CPG）为基础的治疗导致乙肝病毒的高效通关和，HBV携带者小鼠诱导抗HBsAg响应。结论：我们建议从HBV基因组的内源性HBV的CpG寡核苷酸诱导IFN-α的生产，该纳米颗粒的封装的HBV-CpG基可作为HBsAg疫苗的佐剂，也可代表一种强效的治疗剂，用于治疗慢性HBV感染。 （肝胆病2013;)。

tonychant

中国人搞得东西可信度有多高？又想起了闻院士

StephenW

回复 tonychant 的帖子

闻院士是国际公认的科学家.
这项研究是相当感兴趣的, 因为它使用HBV基因组的一部分（而不是HBV的蛋白质）作为免疫刺激剂.

咬牙硬挺

回复 StephenW 的帖子

希望他们开展后续的有可操作性研究，而不是只提出论题发表论文